Use loss of taste and smell as key screening tool for Covid-19, researchers say
Researchers have called for the use of additional coronavirus symptoms to detect new cases, reduce infections and save lives.
In a letter published in The Lancet, the King’s College London team discussed how loss of taste and smell – anosmia – should form part of screening measures for the virus.
The researchers, led by Professor Tim Spector, previously reported that loss of smell and taste is a key predictor of Covid-19 in addition to the most established symptoms of a high temperature and a new, continuous cough.
On May 18, the symptoms were added to the NHS coronavirus symptoms list, weeks after experts first raised concerns that Covid-19 cases were being missed.
However, the importance of the symptom was disputed by some.
The researchers’ additional analysis of the Covid Symptom Study app data and its 3.7 million users sought to quantify the clinical value of recording loss of smell in the population.
They said: “As countries slowly emerge from lockdown measures, it is imperative to correctly contact-trace infected individuals.
“We believe that having added loss of smell and taste to the list of Covid-19 symptoms is of great value as it will help tracing almost 16% of cases that otherwise would have been missed.”
From 76,260 people with symptoms who tested positive for coronavirus up to May 19, 28.5% never reported any fever or cough and 16% reported loss of smell but not fever or cough.
Researchers say the prevalence of loss of smell and taste was three-fold higher in individuals testing positive (65%) than in those testing negative (22%), the strongest single predictor of being infected.
They suggest this means people with loss of smell and taste should self-isolate for at least seven days or until they can be tested.
Prof Spector said: “We believe that loss of smell and taste is a very common Covid-19 symptom, and in fact occurs more often than fever and lasts longer (five days on average compared to only two for fever).
“Infections could be reduced and lives saved now that this non-flu-like symptom is widely recognised and actions are taken.”
The researchers suggest that policymakers should consider these findings and their implications for mass screening as part of other public health measures in key areas such as schools, hospitals, airports and care homes.
Prof Spector said: “Our data suggests that low-cost so-called ‘smell the difference’ screening tests, that are already being used in some workplaces to screen people as they enter buildings, would capture a larger number of positive cases than temperature sensors do.
“We therefore feel that it should form part of a wider public health approach to reducing the infection rate.”